CLSI M23-A3

Clinical and Laboratory Standards Institute document M23-A3–Development of In Vitro Susceptibility Testing Criteria andQuality Control Parameters; Approved Guideline–Third Edition offers guidance for developing interpretive criteria and qualitycontrol ranges for antimicrobial susceptibility tests against aerobic and anaerobic bacteria, and yeasts performed by CLSIantimicrobial susceptibility testing standards. It describes the data utilized by the Antimicrobial Susceptibility Testing andAntifungal subcommittees to establish these interpretive criteria and QC ranges for antimicrobial agents, including MICdistributions against relevant microorganisms, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, and clinicaloutcome data. As antimicrobial agents are used in practice, additional experience accrued may be used to reassess interpretivecriteria or QC ranges. Users of these guidelines should understand that susceptibility test results cannot predict with absolutecertainty clinical outcomes. They should be used along with the best clinical judgment and laboratory support to draw the bestconclusions serving the patient.

Published:

01/01/2008

Number of Pages:

64